<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE collection SYSTEM "BioC.dtd"><collection><source>BioC-API</source><date>20260212</date><key>collection.key</key><document><id>PMC12826186</id><infon key="license">CC BY-NC</infon><passage><infon key="article-id_art-access-id">00098</infon><infon key="article-id_doi">10.1097/MD.0000000000047173</infon><infon key="article-id_pmc">PMC12826186</infon><infon key="article-id_pmid">41560068</infon><infon key="article-id_publisher-id">MD-D-25-09180</infon><infon key="elocation-id">e47173</infon><infon key="issue">3</infon><infon key="kwd">bone mineral density inflammatory bowel disease meta-analysis osteopenia osteoporosis steroid</infon><infon key="license">This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.</infon><infon key="name_0">surname:Li;given-names:Chang-Chun</infon><infon key="name_1">surname:Xu;given-names:Li-Ping</infon><infon key="name_2">surname:Zheng;given-names:Tian-Tian</infon><infon key="name_3">surname:Wu;given-names:Xiao-Li</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">105</infon><infon key="year">2026</infon><offset>0</offset><text>The effects of steroid treatment on osteoporosis in patients with inflammatory bowel disease: A systematic review and meta-analysis</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>132</offset><text>Background:</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>144</offset><text>Patients with inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are often treated with steroids to alleviate their symptoms. Prolonged corticosteroid use can lead to decreased bone mineral density (BMD). However, the impact of steroid treatment regimens on BMD in patients with IBD is not fully understood. This study aimed to investigate the effects of corticosteroid therapy on BMD in IBD patients.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>591</offset><text>Methods:</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>600</offset><text>A predetermined protocol registered in the PROSPERO registry under reference CRD42024518193. We searched the MEDLINE, EMBASE, Web of Science, and Cochrane Library databases to identify studies reporting the BMD of IBD before April 2024. Studies were evaluated using the Newcastle–Ottawa Scale. Sensitivity analyses and Begg’s asymmetric test were used to detect bias.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>972</offset><text>Results:</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>981</offset><text>Following screening and evaluation, a meta-analysis of steroid odds ratios (ORs) of BMD in IBD was conducted based on 18 selected studies, with a total of 27,716 participants. The abnormal BMD in IBD was with an odds ratio (OR) of 2.31 (95% confidence interval [CI]: 1.19–4.48), osteoporosis in IBD with OR of 1.62 (95% CI: 1.02–2.58), osteoporosis in CD with an OR of 1.21 (95% CI: 0.85–1.73), osteoporosis in UC with an OR of 1.00 (95% CI: 0.87–1.16), abnormal BMD in CD with OR of 1.02 (95% CI: 0.99–1.06), abnormal BMD in UC with OR of 1.44 (95% CI: 1.07–1.95).</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1559</offset><text>Conclusion:</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1571</offset><text>Patients diagnosed with IBD who received glucocorticoid therapy did not show a significant increase in osteoporosis (BMD T ≤ −2.5), especially in the UC group, despite having a higher tendency for bone loss (BMD T ≤ −1). The osteoporosis observed in IBD patients may require further comprehensive exploration and clarification.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1915</offset><text>1. Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1931</offset><text>Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic conditions characterized by immune-mediated illnesses of the gastrointestinal tract.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2125</offset><text>Although recent data shows stabilization or decline in western countries, meanwhile, the prevalence of IBD has notably increased in newly industrialized countries across Africa, Asia, and South America. The situation presents a notable challenge for healthcare providers, particularly in developing countries, where there has also been an increase in IBD rates.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2487</offset><text>Corticosteroids are potent for moderate-to-severe CD and UC relapse. The initial prednisolone dosage was 40 mg/d, which was gradually reduced to 5 mg/d at weekly intervals. For steroid-resistant or unresponsive cases, immunosuppressive therapies, such as cyclosporine or infliximab, are recommended. In addition, steroids have no role in maintenance therapy for either disease. The treatment with corticosteroids during IBD should be phased in comparison to antitumor necrosis factor therapy or other therapies that could be used as maintenance therapy. Prolonged corticosteroid administration is associated with reduced bone mineral density (BMD). Since corticosteroids are often used briefly to induce remission in IBD, extended use seems to exceed the recommended guidelines for most patients. This positions the IBD population as an appropriate group for investigating the impact of short-term corticosteroid treatments on bone density.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3432</offset><text>Osteopenia, denoting low bone mass, represents the initial phase in the progression of osteoporosis, a systemic skeletal pathology characterized by reduced bone density and microarchitectural deterioration of bone tissue, leading to increased bone fragility. This condition frequently remains unnoticed until it culminates in fractures, resulting in increased rates of mortality, morbidity, and disability, while also imposing substantial economic burdens.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3889</offset><text>Multiple risk factors contribute to osteoporotic fractures, including, but not limited to, postmenopausal status, vitamin D deficiency, low calcium intake, and prolonged use of specific medications such as glucocorticoids.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4112</offset><text>The relationship between IBD and BMD has been extensively studied; however, the findings have been contradictory. Bernstein et al found that decreased bone density in IBD was related to corticosteroid use rather than the disease itself. However, as the gut-bone axis has been recognized and studied, inflammation and bone density loss caused by IBD are becoming more concerning. Xu et al identified a genetic relationship between IBD and decreased bone density. Wang et al investigated the differentiation of bone marrow mesenchymal stromal cells in IBD-induced bone loss. There is still uncertainty about whether the disease itself directly causes changes in BMD in IBD patients or if the observed osteoporosis is due to related risk factors such as vitamin D deficiency or corticosteroid use. Additionally, differences in osteoporosis prevalence between CD and UC further complicate the matter. For clearer understanding, we conducted a targeted meta-analysis to assess the impact of steroid use on BMD in IBD patients with a focus on the influence of corticosteroids on BMD in this population.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>5209</offset><text>2. Materials and methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>5234</offset><text>2.1. Search strategy</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5255</offset><text>We conducted a systematic review and meta-analysis according to Preferred Reporting Items for Systematic reviews and Meta-Analyses standards, following a predetermined protocol registered in the PROSPERO registry under reference CRD42024518193. Two authors, LCC and XLP, independently searched electronic databases, including MEDLINE, EMBASE, Web of Science, and the Cochrane Library, from inception until April 2024 to identify relevant studies on corticosteroid use in individuals with IBD. The terms and their derivatives were used to retrieve articles on Crohn’s disease, ulcerative colitis, cortisone, low bone density, osteoporosis, osteopenia, steroids, and cortisone.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>5933</offset><text>2.2. Study selection</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5954</offset><text>The inclusion and exclusion criteria for the studies were as follows: original cross-sectional cohort studies on BMD and IBD. Studies providing data for odds ratios (ORs) and 95% confidence intervals (CIs). Diagnoses were categorized using clinical, endoscopic, radiological, and histological data or using the International Classification of Diseases Ninth Revision (ICD-9) or International Classification of Diseases Tenth Revision (ICD-10) codes. BMD was measured using dual-energy X-ray absorptiometry. Studies published in English before April 2024. The exclusion criteria were as follows: cell or animal studies, reviews, case reports, comments, and letters; duplicate study; research on unrelated topics; and studies lacking the necessary data or information.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>6721</offset><text>2.3. Data extraction</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6742</offset><text>Two researchers, LCC and WXL, independently gathered data from each study, encompassing details such as the author’s name, publication year, population and demographic characteristics (age and sex), BMD measurements, and IBD type. Individuals with IBD were classified as either CD or UC to investigate the impact of these conditions on BMD. Additionally, we collected the usual dose grouping data for cortisone regimens that closely aligned with the recommended treatment.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>7217</offset><text>2.4. Quality assessment</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7241</offset><text>Studies were evaluated using the Newcastle–Ottawa Scale (NOS), which scrutinizes 3 main domains: selection of study groups, comparability of groups, and ascertainment of exposure and outcome. Studies receiving 6 or more stars were classified as high-quality.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>7502</offset><text>2.5. Statistical analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7528</offset><text>Two authors, LCC and ZTT, independently conducted the analyses using Stata Statistical Software (version 17.0, College Station). The I2 chi-square statistic was used to quantify the variability between studies and evaluate statistical heterogeneity. Sensitivity analyses were conducted to assess individual study effects and result in stability. Begg’s asymmetric test was used to detect publication bias. Random-effect models were employed for variability.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>7988</offset><text>2.6. Ethics approval and consent to participate</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8036</offset><text>The data for this study were obtained from published literature, and ethical approval and consent to participate were not applicable.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>8170</offset><text>3. Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>8181</offset><text>3.1. Study selection process</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>8210</offset><text>The search strategy used for the meta-analysis of the impact of steroids on BMD in patients with IBD resulted in 1361 publications from the MEDLINE, EMBASE, Web of Science, and Cochrane Library databases. The detailed strategy for the search and its results is presented in Figure S1, Supplemental Digital Content, https://links.lww.com/MD/R140. Of these records, 534 publications were excluded owing to duplication, and 602 articles were excluded after screening the titles and abstracts. A comprehensive investigation revealed that 32 articles were inaccessible or related to literature. After thoroughly reviewing all available texts, it was found that 8 articles were scribed in languages other than English, 1 article comprised a review, 1 article appeared in duplicate, and 165 articles were missing the necessary analytical data, or the data could not be fully obtained. Consequently, 18 articles were deemed to be suitable for inclusion in the final analysis (Fig. 1, Table 1).</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>9196</offset><text>The characteristics of the included studies.</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Author&lt;/th&gt;&lt;th align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Year&lt;/th&gt;&lt;th align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Country&lt;/th&gt;&lt;th align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Number of patients&lt;/th&gt;&lt;th align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Age of patients&lt;/th&gt;&lt;th align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Gender&lt;/th&gt;&lt;th align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Dosage or period of steroid use&lt;/th&gt;&lt;th align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Statistical methods&lt;/th&gt;&lt;th align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Detect parts&lt;/th&gt;&lt;th align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Analysis group&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Abraham et al&lt;sup&gt;&lt;xref rid=&quot;R18&quot; ref-type=&quot;bibr&quot;&gt;18&lt;/xref&gt;&lt;/sup&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2014&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;United States&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;166&lt;break/&gt;(CD: n = 105, UC: n = 61)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;36 ± 15.2&lt;break/&gt;(Mean ± SD)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Male and female&lt;break/&gt;(0.72:1)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Prior use of steroids,&lt;break/&gt;the dosage is not stated&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Multivariable logistic regression&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Lumbar spine and hip&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Abnormal BMD&lt;xref rid=&quot;tab1fn2&quot; ref-type=&quot;table-fn&quot;&gt;*&lt;/xref&gt; in undistinguished IBD,&lt;break/&gt;osteoporosis in undistinguished IBD&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Bundela et al&lt;sup&gt;&lt;xref rid=&quot;R19&quot; ref-type=&quot;bibr&quot;&gt;19&lt;/xref&gt;&lt;/sup&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2017&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;India&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;55&lt;break/&gt;(UC Only)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;31.3&lt;break/&gt;(Mean age)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Male and female&lt;break/&gt;(1.22:1)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Prior use of steroids,&lt;break/&gt;the dosage is not stated&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Multivariable logistic regression&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Lumbar spine and hip&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Abnormal BMD in UC,&lt;break/&gt;osteoporosis in UC&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Cushing et al&lt;sup&gt;&lt;xref rid=&quot;R20&quot; ref-type=&quot;bibr&quot;&gt;20&lt;/xref&gt;&lt;/sup&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2023&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;United States&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1291&lt;break/&gt;(IBD undistinguished)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;57&lt;break/&gt;(Mean age)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Male and female&lt;break/&gt;(0.89:1)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Prior use of steroids,&lt;break/&gt;the dosage is not stated&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Multivariable logistic regression&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Identify using ICD-9 or ICD-10 codes&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Abnormal BMD in undistinguished IBD&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Farraj et al&lt;sup&gt;&lt;xref rid=&quot;R21&quot; ref-type=&quot;bibr&quot;&gt;21&lt;/xref&gt;&lt;/sup&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2022&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;United States&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;18,030&lt;break/&gt;(IBD undistinguished)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;49.70 ± 19.94&lt;break/&gt;(Mean ± SD)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Male and female&lt;break/&gt;(0.89:1)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Chronic use, defined as therapy &amp;gt;3 mo&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Multivariable logistic regression&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Identify using ICD-9&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Osteoporosis in undistinguished IBD&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Graziano et al&lt;sup&gt;&lt;xref rid=&quot;R22&quot; ref-type=&quot;bibr&quot;&gt;22&lt;/xref&gt;&lt;/sup&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2020&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;United States&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;118&lt;break/&gt;(IBD undistinguished)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;67.8 ± 10.4&lt;break/&gt;(Mean ± SD)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Male and female&lt;break/&gt;(0.05:1)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Daily prednisone (any dose) is used for ≥ 3 mo duration before DEXA&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Multivariable logistic regression&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Not Stated&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Abnormal BMD in undistinguished IBD&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Khan et al&lt;sup&gt;&lt;xref rid=&quot;R23&quot; ref-type=&quot;bibr&quot;&gt;23&lt;/xref&gt;&lt;/sup&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2012&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;United States&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1061&lt;break/&gt;(UC only)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;66&lt;break/&gt;(Mean age)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Male&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Prednisone cumulative dose &amp;lt; 180 mg&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Multivariable logistic regression&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Identify using ICD-9 or ICD-10 codes&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Abnormal BMD in UC&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Khan et al&lt;sup&gt;&lt;xref rid=&quot;R24&quot; ref-type=&quot;bibr&quot;&gt;24&lt;/xref&gt;&lt;/sup&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2013&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;United States&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1062&lt;break/&gt;(UC only)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;61&lt;break/&gt;(Median age)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Male&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Received 600–1000 mg cumulative prednisolone&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Multivariable logistic regression&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Identify using ICD-9 codes&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Abnormal BMD in UC&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Khan, et al&lt;sup&gt;&lt;xref rid=&quot;R25&quot; ref-type=&quot;bibr&quot;&gt;25&lt;/xref&gt;&lt;/sup&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2019&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;India&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;106&lt;break/&gt;(CD: n = 35, UC: n = 71)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;34.4 ± 11.3&lt;break/&gt;(Mean ± SD)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Male and female&lt;break/&gt;(2.03:1)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Most patients received short courses of corticosteroids (&amp;lt;3 mo)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Multivariable logistic regression&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Not stated&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Abnormal BMD in undistinguished IBD&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Lo, et al&lt;sup&gt;&lt;xref rid=&quot;R26&quot; ref-type=&quot;bibr&quot;&gt;26&lt;/xref&gt;&lt;/sup&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2020&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Denmark&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;123&lt;break/&gt;(CD: n = 62, UC: n = 61)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;46.5&lt;break/&gt;(Mean age)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Male and female&lt;break/&gt;(0.53:1)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Received ≥ 500 mg cumulative prednisolone&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Multivariable logistic regression&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;The lumbar spine, femoral neck, and total hip&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Abnormal BMD in undistinguished IBD,&lt;break/&gt;Abnormal BMD in CD,&lt;break/&gt;Abnormal BMD in UC,&lt;break/&gt;osteoporosis in CD,&lt;break/&gt;osteoporosis in UC&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Miranda-Bautista et al&lt;sup&gt;&lt;xref rid=&quot;R27&quot; ref-type=&quot;bibr&quot;&gt;27&lt;/xref&gt;&lt;/sup&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2019&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Spain&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;261&lt;break/&gt;(CD: n = 93, UC: n = 168)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;44.9 ± 14.7&lt;break/&gt;(Mean ± SD)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Male and female&lt;break/&gt;(0.76:1)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;The dosing used was 1 mg/kg of weight/d (maximum 60 mg/d) of prednisone during 1 or 2 wk and a decrease of 10 mg/d each week until 20 mg/d; after this dose, the decrease falls to 5 mg/d each week until suppression.&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Multivariable logistic regression&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Spine or hip DXA&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Abnormal BMD in undistinguished IBD&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Morrow et al&lt;sup&gt;&lt;xref rid=&quot;R28&quot; ref-type=&quot;bibr&quot;&gt;28&lt;/xref&gt;&lt;/sup&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2023&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;United States&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12&lt;break/&gt;(IBD undistinguished)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12.76&lt;break/&gt;(9.56–15.46)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Male and female&lt;break/&gt;(Not stated detail)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6 mo or longer of steroids&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Multivariable logistic regression&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Not stated&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Abnormal BMD in undistinguished IBD&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Navaneethan et al&lt;sup&gt;&lt;xref rid=&quot;R29&quot; ref-type=&quot;bibr&quot;&gt;29&lt;/xref&gt;&lt;/sup&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2011&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;United States&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;342&lt;break/&gt;(UC only)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;47.05 ± 15.68&lt;break/&gt;(Mean ± SD)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Male and female&lt;break/&gt;(1.05:1)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Any corticosteroid use&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Multivariable logistic regression&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;The lumbar spine, femoral neck, and total hip&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Osteoporosis in UC&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;de Silva et al&lt;sup&gt;&lt;xref rid=&quot;R30&quot; ref-type=&quot;bibr&quot;&gt;30&lt;/xref&gt;&lt;/sup&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2009&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Sri Lankans&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;111&lt;break/&gt;(CD: n = 28, UC: n = 83)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;42.5 ± 14.19&lt;break/&gt;(Mean ± SD)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Male and female&lt;break/&gt;(0.63:1)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Choroid use was defined as the continuous use of systemic steroids for &amp;gt;3 mo&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Multivariable logistic regression&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Not stated&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Osteoporosis in undistinguished IBD&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Semeao et al&lt;sup&gt;&lt;xref rid=&quot;R31&quot; ref-type=&quot;bibr&quot;&gt;31&lt;/xref&gt;&lt;/sup&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1999&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;United States&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;119&lt;break/&gt;(CD only)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;16.2 ± 4.1&lt;break/&gt;(Mean ± SD)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Male and female&lt;break/&gt;(1.53:1)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Total (mg): 10,893 ± 13,709&lt;break/&gt;(Mean ± SD),&lt;break/&gt;Total months: 19.1 ± 23.5&lt;break/&gt;(Mean ± SD)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Multivariable logistic regression&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Lumbar vertebrae (L1–L4)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Abnormal BMD in CD&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Schüle et al&lt;sup&gt;&lt;xref rid=&quot;R32&quot; ref-type=&quot;bibr&quot;&gt;32&lt;/xref&gt;&lt;/sup&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2016&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Swiss&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3127&lt;break/&gt;(IBD undistinguished)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;41.7&lt;break/&gt;(1.3–91.5)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Male and female&lt;break/&gt;(1.03:1)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Not stated&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Multivariable logistic regression&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Lumbar spine and hip&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Abnormal BMD in undistinguished IBD&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Tsironi et al&lt;sup&gt;&lt;xref rid=&quot;R33&quot; ref-type=&quot;bibr&quot;&gt;33&lt;/xref&gt;&lt;/sup&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2007&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Greece&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;122&lt;break/&gt;(CD: n = 66, UC: n = 56)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;44.8 ± 14.8&lt;break/&gt;(Mean ± SD)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Male and female&lt;break/&gt;(0.94:1)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;≥5 g&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Stepwise linear regression analysis&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;The spine (L2–L4) and the neck of the left proximal femur&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Abnormal BMD in undistinguished IBD&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Targownik et al&lt;sup&gt;&lt;xref rid=&quot;R34&quot; ref-type=&quot;bibr&quot;&gt;34&lt;/xref&gt;&lt;/sup&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2013&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Canada&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1230&lt;break/&gt;(CD: n = 719, UC: n = 511)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;51 (40–62)&lt;break/&gt;Median age (IQR)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Male and female&lt;break/&gt;(0.32:1)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Not stated&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Multivariable logistic regression&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;The lumbar, femoral neck, trochanter, and total hip&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Osteoporosis in CD&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yin et al&lt;sup&gt;&lt;xref rid=&quot;R35&quot; ref-type=&quot;bibr&quot;&gt;35&lt;/xref&gt;&lt;/sup&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2022&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;China&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;380&lt;break/&gt;(CD: n = 212, UC: n = 168)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;35.23 ± 12.04&lt;break/&gt;(Mean ± SD)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Male and female&lt;break/&gt;(1.14:1)&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Not stated&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Multivariable logistic regression&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;The lumbar spine, femoral neck, or total hip&lt;/td&gt;&lt;td align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Abnormal BMD in undistinguished IBD,&lt;break/&gt;Abnormal BMD in undistinguished UC&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>9241</offset><text>Author	Year	Country	Number of patients	Age of patients	Gender	Dosage or period of steroid use	Statistical methods	Detect parts	Analysis group	 	Abraham et al	2014	United States	166(CD: n = 105, UC: n = 61)	36 ± 15.2(Mean ± SD)	Male and female(0.72:1)	Prior use of steroids,the dosage is not stated	Multivariable logistic regression	Lumbar spine and hip	Abnormal BMD* in undistinguished IBD,osteoporosis in undistinguished IBD	 	Bundela et al	2017	India	55(UC Only)	31.3(Mean age)	Male and female(1.22:1)	Prior use of steroids,the dosage is not stated	Multivariable logistic regression	Lumbar spine and hip	Abnormal BMD in UC,osteoporosis in UC	 	Cushing et al	2023	United States	1291(IBD undistinguished)	57(Mean age)	Male and female(0.89:1)	Prior use of steroids,the dosage is not stated	Multivariable logistic regression	Identify using ICD-9 or ICD-10 codes	Abnormal BMD in undistinguished IBD	 	Farraj et al	2022	United States	18,030(IBD undistinguished)	49.70 ± 19.94(Mean ± SD)	Male and female(0.89:1)	Chronic use, defined as therapy &gt;3 mo	Multivariable logistic regression	Identify using ICD-9	Osteoporosis in undistinguished IBD	 	Graziano et al	2020	United States	118(IBD undistinguished)	67.8 ± 10.4(Mean ± SD)	Male and female(0.05:1)	Daily prednisone (any dose) is used for ≥ 3 mo duration before DEXA	Multivariable logistic regression	Not Stated	Abnormal BMD in undistinguished IBD	 	Khan et al	2012	United States	1061(UC only)	66(Mean age)	Male	Prednisone cumulative dose &lt; 180 mg	Multivariable logistic regression	Identify using ICD-9 or ICD-10 codes	Abnormal BMD in UC	 	Khan et al	2013	United States	1062(UC only)	61(Median age)	Male	Received 600–1000 mg cumulative prednisolone	Multivariable logistic regression	Identify using ICD-9 codes	Abnormal BMD in UC	 	Khan, et al	2019	India	106(CD: n = 35, UC: n = 71)	34.4 ± 11.3(Mean ± SD)	Male and female(2.03:1)	Most patients received short courses of corticosteroids (&lt;3 mo)	Multivariable logistic regression	Not stated	Abnormal BMD in undistinguished IBD	 	Lo, et al	2020	Denmark	123(CD: n = 62, UC: n = 61)	46.5(Mean age)	Male and female(0.53:1)	Received ≥ 500 mg cumulative prednisolone	Multivariable logistic regression	The lumbar spine, femoral neck, and total hip	Abnormal BMD in undistinguished IBD,Abnormal BMD in CD,Abnormal BMD in UC,osteoporosis in CD,osteoporosis in UC	 	Miranda-Bautista et al	2019	Spain	261(CD: n = 93, UC: n = 168)	44.9 ± 14.7(Mean ± SD)	Male and female(0.76:1)	The dosing used was 1 mg/kg of weight/d (maximum 60 mg/d) of prednisone during 1 or 2 wk and a decrease of 10 mg/d each week until 20 mg/d; after this dose, the decrease falls to 5 mg/d each week until suppression.	Multivariable logistic regression	Spine or hip DXA	Abnormal BMD in undistinguished IBD	 	Morrow et al	2023	United States	12(IBD undistinguished)	12.76(9.56–15.46)	Male and female(Not stated detail)	6 mo or longer of steroids	Multivariable logistic regression	Not stated	Abnormal BMD in undistinguished IBD	 	Navaneethan et al	2011	United States	342(UC only)	47.05 ± 15.68(Mean ± SD)	Male and female(1.05:1)	Any corticosteroid use	Multivariable logistic regression	The lumbar spine, femoral neck, and total hip	Osteoporosis in UC	 	de Silva et al	2009	Sri Lankans	111(CD: n = 28, UC: n = 83)	42.5 ± 14.19(Mean ± SD)	Male and female(0.63:1)	Choroid use was defined as the continuous use of systemic steroids for &gt;3 mo	Multivariable logistic regression	Not stated	Osteoporosis in undistinguished IBD	 	Semeao et al	1999	United States	119(CD only)	16.2 ± 4.1(Mean ± SD)	Male and female(1.53:1)	Total (mg): 10,893 ± 13,709(Mean ± SD),Total months: 19.1 ± 23.5(Mean ± SD)	Multivariable logistic regression	Lumbar vertebrae (L1–L4)	Abnormal BMD in CD	 	Schüle et al	2016	Swiss	3127(IBD undistinguished)	41.7(1.3–91.5)	Male and female(1.03:1)	Not stated	Multivariable logistic regression	Lumbar spine and hip	Abnormal BMD in undistinguished IBD	 	Tsironi et al	2007	Greece	122(CD: n = 66, UC: n = 56)	44.8 ± 14.8(Mean ± SD)	Male and female(0.94:1)	≥5 g	Stepwise linear regression analysis	The spine (L2–L4) and the neck of the left proximal femur	Abnormal BMD in undistinguished IBD	 	Targownik et al	2013	Canada	1230(CD: n = 719, UC: n = 511)	51 (40–62)Median age (IQR)	Male and female(0.32:1)	Not stated	Multivariable logistic regression	The lumbar, femoral neck, trochanter, and total hip	Osteoporosis in CD	 	Yin et al	2022	China	380(CD: n = 212, UC: n = 168)	35.23 ± 12.04(Mean ± SD)	Male and female(1.14:1)	Not stated	Multivariable logistic regression	The lumbar spine, femoral neck, or total hip	Abnormal BMD in undistinguished IBD,Abnormal BMD in undistinguished UC	 	</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>14109</offset><text>BMD = bone mineral density, CD = Crohn’s disease, DEXA = dual-energy X-ray absorptiometry, IBD = inflammatory bowel diseases, ICD = International Classification of Diseases, SD = standard deviation, UC = ulcerative colitis.</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_footnote</infon><offset>14339</offset><text>Abnormal BMD including osteoporosis (BMD T ≤ −2.5) and osteopenia (BMD T ≤ −1).</text></passage><passage><infon key="file">medi-105-e47173-g001.jpg</infon><infon key="id">F1</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>14435</offset><text>Study selection process. Source: Page et al. PRISMA = Preferred Reporting Items for Systematic reviews and Meta-Analyses, WOS = Web of Science.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>14579</offset><text>3.2. Abnormal BMD and IBD</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>14605</offset><text>We conducted a meta-analysis using data from 10 articles to investigate abnormal BMD, encompassing osteopenia and osteoporosis, in the context of IBD, which comprises both UC and CD. Furthermore, we present subgroup data on bone mass abnormalities in patients diagnosed with CD and UC.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>14891</offset><text>In comparison of the effects of corticosteroids on bone mass in various groups without distinguishing between disease types, most studies demonstrated adverse effects on bone mass, except for 1 (Khan). In the IBD group, combined with the associated risk, the odds ratio was 2.31 (95% CI: 1.19–4.48, I2 = 98.4%, P &lt; .001). In the CD group, combined with the associated risk of 2 research (Lo, Semeao), an odds ratio was 1.02 (95% CI: 0.99–1.06, I2 = 0%, P = .782). Conversely, in the UC group, the influence of corticosteroids on bone mass exhibited greater prominence than in the CD group, producing a combined odds ratio of 1.44 (95% CI: 1.07–1.95, I2 = 86.9%, P &lt; .001) from 5 research (Lo, Yin, Bundela, Khan, Khan; Fig. 2).</text></passage><passage><infon key="file">medi-105-e47173-g002.jpg</infon><infon key="id">F2</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>15649</offset><text>Abnormal bone density (including osteopenia and osteoporosis) is grouped by IBD (undistinguished UC and CD), CD, and UC. CD = Crohn’s disease, CI = confidence interval, IBD = inflammatory bowel diseases, NOS = Newcastle–Ottawa Scale, OR = odds ratio, UC = ulcerative colitis.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>15929</offset><text>3.3. Osteoporosis and IBD</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>15955</offset><text>An analysis of 5 studies (Abraham, Lo, Miranda-Bautista, Farraj, de Silva) on steroid use and osteoporosis in patients with IBD revealed that steroid use was associated with a reduced overall risk of osteoporosis, with an odds ratio of 1.62 (95% CI: 1.02–2.58, I2 = 98.5%, P &lt; .001). The analysis of 2 researches (Lo, Targownik) was observed that the risk of osteoporosis with corticosteroids appeared to be elevated in patients with CD with an odds ratio of 1.21 (95% CI: 0.85–1.73, I2 = 92.1%, P &lt; .001); however, the conclusions drawn from the literature exhibited marked variability compared to previous findings on bone mass abnormalities. Furthermore, from the analysis of 4 researches (Lo, Bundela, Targownik, Navaneethan), cortisone-related osteoporosis showed an overall reduction in patients with UC compared to bone mass abnormalities with an odds ratio of 1.00 (95% CI: 0.87–1.16, I2 = 21.2%, P = .283). Data from each subgroup was combined to synthesize, and the analysis indicated a reduced risk of osteoporosis associated with corticosteroid compared to abnormal BMD, with an odds ratio of 1.23 (95% CI: 1.04–1.46, I2 = 96.6%, P &lt; .001; Fig. 3).</text></passage><passage><infon key="file">medi-105-e47173-g003.jpg</infon><infon key="id">F3</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>17156</offset><text>Osteoporosis grouped by IBD (undistinguished UC and CD), CD, and UC. CD = Crohn’s disease, CI = confidence interval, IBD = inflammatory bowel diseases, NOS = Newcastle–Ottawa Scale, OR = odds ratio, UC = ulcerative colitis.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>17384</offset><text>3.4. Abnormal BMD and CD</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>17409</offset><text>Our analysis entailed examining the data from patients diagnosed with Crohn’s. We conducted subgroup analyses focusing on osteoporosis and abnormal BMD encompassing osteoporosis and osteopenia. Notably, although they exhibited differences in contrast to available literature, the conclusions drawn from each subgroup suggested a negligible overall impact of cortisone on bone mass in CD patients, yielding an odds ratio of 1.07 (95% CI: 0.99–1.15, I2 = 77%, P = .005; Fig. 4).</text></passage><passage><infon key="file">medi-105-e47173-g004.jpg</infon><infon key="id">F4</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>17898</offset><text>CD grouped by abnormal bone density (including osteopenia and osteoporosis) and osteoporosis. CI = confidence interval, CD = Crohn’s disease, NOS = Newcastle–Ottawa Scale, OR = odds ratio.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>18091</offset><text>3.5. Abnormal BMD and UC</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>18116</offset><text>In a study involving UC patients, subsets were examined to assess osteoporosis and abnormal BMD. Following analysis, it was determined that BMD showed no substantial predisposition to abnormalities attributable to cortisone influence, as evidenced by an odds ratio of 1.19 (95% CI: 1.05–1.36, I2 = 78.1%, P &lt; .001; Fig. 5)</text></passage><passage><infon key="file">medi-105-e47173-g005.jpg</infon><infon key="id">F5</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>18449</offset><text>UC grouped by abnormal bone density (including osteopenia and osteoporosis) and Osteoporosis. CI = confidence interval, NOS = Newcastle–Ottawa Scale, OR = odds ratio, UC = ulcerative colitis.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>18643</offset><text>3.6. Quality assessment</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>18667</offset><text>The NOS instrument was used to assess the risk of bias indicators. A moderate level of bias was identified, with most studies exhibiting an acceptable approach for study selection, comparability, and exposure ascertainment. Nonetheless, a deficiency in follow-up data collection resulted in an inability to derive scores for the pertinent components of the NOS. The detailed scores are presented in Figure S2, Supplemental Digital Content, https://links.lww.com/MD/R140. Inspection of the funnel plot and conducting Begg’s regression test for clinical and endoscopic remission analyses did not suggest the presence of publication bias. The funnel plot and Begg’s result are presented in Figure S3A, B, Supplemental Digital Content, https://links.lww.com/MD/R140. And the sensitivity analyses result is presented in Figure S3C, Supplemental Digital Content, https://links.lww.com/MD/R140.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>19559</offset><text>4. Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>19573</offset><text>In this study, we investigated the impact of corticosteroid treatment on BMD in individuals with IBD. Our analysis revealed a demonstrable correlation between corticosteroid drug treatment and reduced BMD, encompassing osteoporosis and low bone mass. Nevertheless, when osteoporosis is considered the focal point of the inquiry, corticosteroid treatment is not a significant risk factor in the UC group. A comprehensive analysis revealed that steroid therapy is not a significant risk factor for decreasing bone mass in CD group. These findings indicate that while steroid therapy protocols in IBD patients may contribute to diminished BMD, treatment does not significantly increase the risk of osteoporosis.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>20282</offset><text>The administration of corticosteroid drugs is crucial in managing patients with IBD, not only because of their widespread availability in various medical facilities but also because of their superior efficacy in initiating remission at the onset. However, corticosteroid medications pose several risks, including osteoporosis. Long-term corticosteroid use is strongly associated with osteoporosis. However, the use of corticosteroids is advised explicitly during the induction of the remission phase for patients suffering from IBD. Considerable attention should be given to monitoring the effects of medication on BMD during this phase.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>20920</offset><text>The relationship between IBD and osteoporosis is intricate and remains a subject of debate in medical research. While some studies suggest a correlation between osteoporosis and corticosteroid use, others propose that IBD itself may be a causative factor. Factors such as vitamin D deficiency and malnutrition are related to osteoporosis. Our analysis indicates that most corticosteroid medications is not a significant risk factor of osteoporosis in IBD treatment. Malnutrition, decreased body mass index, vitamin D deficiency, and prolonged corticosteroid use are also interrelated with the progression of IBD. Consequently, heightened attention to the close association between IBD and osteoporosis is required. In other words, BMD may be secondarily affected in the ongoing state of intestinal inflammation.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>21732</offset><text>Previous studies have investigated the correlation between osteoporosis and IBD. It has been observed that CD patients demonstrate a higher prevalence of abnormal BMD than UC patients, a finding consistent with our own. A study on the UC group also revealed that BMD was adversely impacted, irrespective of corticosteroid use. Moreover, the influence of corticosteroids on bone mass has conventionally been examined within a multifaceted framework rather than through individual analysis. However, glucocorticoids are a concern in clinical applications owing to their various side effects. It has been established that corticosteroids reduce BMD, and clinical variability in BMD levels indicates diverse prognosis and treatment options.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>22469</offset><text>Drug use has the potential to alter disease progression. The impact of corticosteroids on BMD in patients with IBD has long been recognized. We found that much of the literature assessed corticosteroid administration in terms of cumulative dosage or duration of steroid use during the research process. This implies that intermittent application of steroids is insufficient to cause protracted, severe bone damage that may have been recognized before. However, in the enduring management of IBD patients, the persistent risk of recurrence and exacerbation necessitates further investigation of the frequency of periodic corticosteroid application.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>23117</offset><text>In summary, treatments that induce remission through glucocorticoids have been found to not significantly reduce BMD during active disease. However, this does not mean that prolonged use of corticosteroids or glucocorticoids in high doses could not lead to osteoporosis in cases where the disease is challenging to resolve or recurs frequently. As a result, the use of cortisone has inconsistent effects on BMD changes in patients with IBD, yielding contradictory results. It is of particular interest to ascertain whether promptly controlling inflammation confers benefits in preserving BMD when the inflammatory condition of intestinal lesions affects the systemic state. This inquiry also encompasses the potential bone-preserving effects of corticosteroid administration in patients with IBD, and the observed impact of IBD on BMD. Exploration of the duration and frequency of corticosteroid application is important in patients diagnosed with IBD.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>24070</offset><text>This article has some limitations. Although CD was grouped by abnormal bone density and UC was grouped by osteoporosis, neither showed significant heterogeneity on its own; heterogeneity still appeared when the studies were combined across different groups. In Figures 2 and 3, when we analyzed IBD by disease type, the I2-value decreased, and in Figures 4 and 5, the I2-value between osteoporosis and abnormal bone density also decreased in the CD and UC groups. This suggests that disease types may contribute to heterogeneity and that a more precise grouping of IBD types (CD and UC) and controls for bone density (osteoporosis and osteopenia) is necessary to reduce heterogeneity. Additionally, as shown in Figure 4, the heterogeneity in the osteoporosis group within CD is high. Comparing the 2 studies, we found that the group with a higher proportion of women in the age range closer to perimenopause exhibited a higher tendency for osteoporosis. This also suggests that gender and age are factors contributing to heterogeneity. However, the same trend of difference did not show heterogeneity in the osteopenia and osteoporosis groups, which may mean that the study of bone density by age and gender is not continuous but rather shows a stepped change. That is, the proportion of menopausal women in the study population and their impact on osteoporosis in IBD patients need special attention. Various factors might have led to heterogeneity, but many could not be assessed. Additionally, varying concerns across different studies and time periods led to inconsistencies in grouping and data collection, which restricted analysis and limited access to raw data, thereby restraining further subgroup analyses.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>25787</offset><text>This research is a meta-analysis of multiple studies because it is challenging to control for variables owing to the different purposes of the studies. There are discernible effects on bone density, influenced by factors such as age, sex, and vitamin D levels. However, these variables have not been consistently elucidated in the literature, suggesting potential bias in the findings. The scarcity of data on Crohn’s also heightens the potential for bias in the analysis. These conclusions require validation through more rigorous clinical trials. However, based on existing studies, these findings are important for further understanding the relationship between IBD and osteoporosis.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>26476</offset><text>5. Conclusion</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>26490</offset><text>Patients diagnosed with IBD who underwent glucocorticoid therapy exhibited the absence of a significant risk of osteoporosis, despite an elevated propensity for bone loss. Osteoporosis in IBD patients may require further comprehensive exploration and clarification.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">title_1</infon><offset>26756</offset><text>Author contributions</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>26777</offset><text>Conceptualization: Chang-Chun Li, Li-Ping Xu.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>26823</offset><text>Data curation: Chang-Chun Li, Li-Ping Xu, Tian-Tian Zheng, Xiao-Li Wu.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>26894</offset><text>Formal analysis: Chang-Chun Li, Li-Ping Xu, Tian-Tian Zheng, Xiao-Li Wu.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>26967</offset><text>Investigation: Chang-Chun Li, Tian-Tian Zheng, Xiao-Li Wu.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>27026</offset><text>Methodology: Chang-Chun Li, Li-Ping Xu.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>27066</offset><text>Project administration: Chang-Chun Li, Li-Ping Xu.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>27117</offset><text>Software: Chang-Chun Li, Tian-Tian Zheng.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>27159</offset><text>Supervision: Chang-Chun Li.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>27187</offset><text>Validation: Tian-Tian Zheng.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>27216</offset><text>Visualization: Chang-Chun Li.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>27246</offset><text>Writing – original draft: Chang-Chun Li, Li-Ping Xu.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>27301</offset><text>Writing – review &amp; editing: Chang-Chun Li, Li-Ping Xu, Tian-Tian Zheng, Xiao-Li Wu.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>27387</offset><text>Supplementary Material</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote_title</infon><offset>27410</offset><text>Abbreviations:</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>27425</offset><text>BMD</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>27429</offset><text>bone mineral density</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>27450</offset><text>CD</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>27453</offset><text>Crohn’s disease</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>27471</offset><text>CI</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>27474</offset><text>confidence interval</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>27494</offset><text>IBD</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>27498</offset><text>inflammatory bowel diseases</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>27526</offset><text>NOS</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>27530</offset><text>Newcastle–Ottawa Scale</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>27555</offset><text>OR</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>27558</offset><text>odds ratio</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>27569</offset><text>UC</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>27572</offset><text>ulcerative colitis</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>27591</offset><text>All data generated or analyzed during this study are included in this published article [and its supplementary information files].</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>27722</offset><text>Supplemental Digital Content is available for this article.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>27782</offset><text>How to cite this article: Li C-C, Xu L-P, Zheng T-T, Wu X-L. The effects of steroid treatment on osteoporosis in patients with inflammatory bowel disease: A systematic review and meta-analysis. Medicine 2026;105:3(e47173).</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>28005</offset><text>CL and LX contributed to this article equally.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>28052</offset><text>The authors have no funding and conflicts of interest to disclose.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>28119</offset><text>References</text></passage><passage><infon key="fpage">307</infon><infon key="lpage">17</infon><infon key="name_0">surname:Hyun;given-names:HK</infon><infon key="name_1">surname:Cheon;given-names:JH</infon><infon key="pub-id_pmid">39774122</infon><infon key="section_type">REF</infon><infon key="source">Gut Liver</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">2025</infon><offset>28130</offset><text>Metabolic disorders and inflammatory bowel diseases.</text></passage><passage><infon key="fpage">2769</infon><infon key="lpage">78</infon><infon key="name_0">surname:Ng;given-names:SC</infon><infon key="name_1">surname:Shi;given-names:HY</infon><infon key="name_2">surname:Hamidi;given-names:N</infon><infon key="pub-id_pmid">29050646</infon><infon key="section_type">REF</infon><infon key="source">Lancet</infon><infon key="type">ref</infon><infon key="volume">390</infon><infon key="year">2017</infon><offset>28183</offset><text>Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.</text></passage><passage><infon key="fpage">497</infon><infon key="lpage">8</infon><infon key="name_0">surname:Barrett;given-names:K</infon><infon key="name_1">surname:Saxena;given-names:S</infon><infon key="name_2">surname:Pollok;given-names:R</infon><infon key="pub-id_pmid">30262630</infon><infon key="section_type">REF</infon><infon key="source">Br J Gen Pract</infon><infon key="type">ref</infon><infon key="volume">68</infon><infon key="year">2018</infon><offset>28318</offset><text>Using corticosteroids appropriately in inflammatory bowel disease: a guide for primary care.</text></passage><passage><infon key="fpage">15</infon><infon key="lpage">24</infon><infon key="name_0">surname:Williams;given-names:JG</infon><infon key="name_1">surname:Alam;given-names:MF</infon><infon key="name_2">surname:Alrubaiy;given-names:L</infon><infon key="pub-id_pmid">27595142</infon><infon key="section_type">REF</infon><infon key="source">Lancet Gastroenterol Hepatol</infon><infon key="type">ref</infon><infon key="volume">1</infon><infon key="year">2016</infon><offset>28411</offset><text>Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial.</text></passage><passage><infon key="fpage">571</infon><infon key="lpage">607</infon><infon key="name_0">surname:Mowat;given-names:C</infon><infon key="name_1">surname:Cole;given-names:A</infon><infon key="name_2">surname:Windsor;given-names:A</infon><infon key="pub-id_pmid">21464096</infon><infon key="section_type">REF</infon><infon key="source">Gut</infon><infon key="type">ref</infon><infon key="volume">60</infon><infon key="year">2011</infon><offset>28565</offset><text>Guidelines for the management of inflammatory bowel disease in adults.</text></passage><passage><infon key="fpage">31</infon><infon key="lpage">47</infon><infon key="name_0">surname:Barrett-Connor;given-names:E</infon><infon key="name_1">surname:Black;given-names:D</infon><infon key="name_2">surname:Bonjour;given-names:J-P</infon><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="volume">921</infon><infon key="year">2003</infon><offset>28636</offset><text>Prevention and Management of Osteoporosis: Report of a WHO Scientific Group.</text></passage><passage><infon key="fpage">818</infon><infon key="lpage">39</infon><infon key="name_0">surname:Qaseem;given-names:A</infon><infon key="name_1">surname:Forciea;given-names:MA</infon><infon key="name_2">surname:McLean;given-names:RM</infon><infon key="pub-id_pmid">28492856</infon><infon key="section_type">REF</infon><infon key="source">Ann Intern Med</infon><infon key="type">ref</infon><infon key="volume">166</infon><infon key="year">2017</infon><offset>28713</offset><text>Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians.</text></passage><passage><infon key="fpage">250</infon><infon key="lpage">6</infon><infon key="name_0">surname:Bernstein;given-names:CN</infon><infon key="name_1">surname:Seeger;given-names:LL</infon><infon key="name_2">surname:Sayre;given-names:JW</infon><infon key="name_3">surname:Anton;given-names:PA</infon><infon key="name_4">surname:Artinian;given-names:L</infon><infon key="name_5">surname:Shanahan;given-names:F</infon><infon key="pub-id_pmid">7754804</infon><infon key="section_type">REF</infon><infon key="source">J Bone Miner Res</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">1995</infon><offset>28876</offset><text>Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis.</text></passage><passage><infon key="fpage">1148107</infon><infon key="name_0">surname:Xu;given-names:D</infon><infon key="name_1">surname:Chen;given-names:Y</infon><infon key="name_2">surname:Gao;given-names:X</infon><infon key="pub-id_pmid">37275908</infon><infon key="section_type">REF</infon><infon key="source">Front Immunol</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">2023</infon><offset>28989</offset><text>The genetically predicted causal relationship of inflammatory bowel disease with bone mineral density and osteoporosis: evidence from two-sample mendelian randomization.</text></passage><passage><infon key="fpage">115953</infon><infon key="name_0">surname:Wang;given-names:H</infon><infon key="name_1">surname:Guo;given-names:J</infon><infon key="name_2">surname:Li;given-names:L</infon><infon key="pub-id_pmid">40616843</infon><infon key="section_type">REF</infon><infon key="source">Cell Rep</infon><infon key="type">ref</infon><infon key="volume">44</infon><infon key="year">2025</infon><offset>29159</offset><text>FTO SUMOylation regulates the differentiation of bone marrow mesenchymal stromal cells in inflammatory bowel disease-induced bone loss.</text></passage><passage><infon key="fpage">G191</infon><infon key="lpage">201</infon><infon key="name_0">surname:Ghishan;given-names:FK</infon><infon key="name_1">surname:Kiela;given-names:PR</infon><infon key="pub-id_pmid">21088237</infon><infon key="section_type">REF</infon><infon key="source">Am J Physiol Gastrointest Liver Physiol</infon><infon key="type">ref</infon><infon key="volume">300</infon><infon key="year">2011</infon><offset>29295</offset><text>Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases.</text></passage><passage><infon key="fpage">315</infon><infon key="lpage">9</infon><infon key="name_0">surname:Targownik;given-names:LE</infon><infon key="name_1">surname:Bernstein;given-names:CN</infon><infon key="name_2">surname:Leslie;given-names:WD</infon><infon key="pub-id_pmid">24139749</infon><infon key="section_type">REF</infon><infon key="source">Maturitas</infon><infon key="type">ref</infon><infon key="volume">76</infon><infon key="year">2013</infon><offset>29388</offset><text>Inflammatory bowel disease and the risk of osteoporosis and fracture.</text></passage><passage><infon key="fpage">269</infon><infon key="name_0">surname:Vernia;given-names:F</infon><infon key="name_1">surname:Valvano;given-names:M</infon><infon key="name_2">surname:Longo;given-names:S</infon><infon key="name_3">surname:Cesaro;given-names:N</infon><infon key="name_4">surname:Viscido;given-names:A</infon><infon key="name_5">surname:Latella;given-names:G</infon><infon key="pub-id_pmid">35057450</infon><infon key="section_type">REF</infon><infon key="source">Nutrients</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">2022</infon><offset>29458</offset><text>Vitamin D in inflammatory bowel diseases. Mechanisms of action and therapeutic implications.</text></passage><passage><infon key="fpage">125</infon><infon key="lpage">36</infon><infon key="name_0">surname:Mouli;given-names:VP</infon><infon key="name_1">surname:Ananthakrishnan;given-names:AN</infon><infon key="pub-id_pmid">24236989</infon><infon key="section_type">REF</infon><infon key="source">Aliment Pharmacol Ther</infon><infon key="type">ref</infon><infon key="volume">39</infon><infon key="year">2014</infon><offset>29551</offset><text>Review article: vitamin D and inflammatory bowel diseases.</text></passage><passage><infon key="fpage">313</infon><infon key="lpage">9</infon><infon key="name_0">surname:Jahnsen;given-names:J</infon><infon key="name_1">surname:Falch;given-names:JA</infon><infon key="name_2">surname:Aadland;given-names:E</infon><infon key="name_3">surname:Mowinckel;given-names:P</infon><infon key="pub-id_pmid">9135518</infon><infon key="section_type">REF</infon><infon key="source">Gut</infon><infon key="type">ref</infon><infon key="volume">40</infon><infon key="year">1997</infon><offset>29610</offset><text>Bone mineral density is reduced in patients with crohn’s disease but not in patients with ulcerative colitis: a population based study.</text></passage><passage><infon key="fpage">n71</infon><infon key="name_0">surname:Page;given-names:MJ</infon><infon key="name_1">surname:McKenzie;given-names:JE</infon><infon key="name_2">surname:Bossuyt;given-names:PM</infon><infon key="pub-id_pmid">33782057</infon><infon key="section_type">REF</infon><infon key="source">BMJ</infon><infon key="type">ref</infon><infon key="volume">372</infon><infon key="year">2021</infon><offset>29748</offset><text>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.</text></passage><passage><infon key="fpage">603</infon><infon key="lpage">5</infon><infon key="name_0">surname:Stang;given-names:A</infon><infon key="pub-id_pmid">20652370</infon><infon key="section_type">REF</infon><infon key="source">Eur J Epidemiol</infon><infon key="type">ref</infon><infon key="volume">25</infon><infon key="year">2010</infon><offset>29830</offset><text>Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.</text></passage><passage><infon key="fpage">1878</infon><infon key="lpage">84</infon><infon key="name_0">surname:Abraham;given-names:BP</infon><infon key="name_1">surname:Prasad;given-names:P</infon><infon key="name_2">surname:Malaty;given-names:HM</infon><infon key="pub-id_pmid">24619280</infon><infon key="section_type">REF</infon><infon key="source">Dig Dis Sci</infon><infon key="type">ref</infon><infon key="volume">59</infon><infon key="year">2014</infon><offset>29957</offset><text>Vitamin D deficiency and corticosteroid use are risk factors for low bone mineral density in inflammatory bowel disease patients.</text></passage><passage><infon key="fpage">193</infon><infon key="lpage">6</infon><infon key="name_0">surname:Bundela;given-names:RPS</infon><infon key="name_1">surname:Ashdhir;given-names:P</infon><infon key="name_2">surname:Narayan;given-names:KS</infon><infon key="name_3">surname:Jain;given-names:M</infon><infon key="name_4">surname:Pokharna;given-names:RK</infon><infon key="name_5">surname:Nijhawan;given-names:S</infon><infon key="pub-id_pmid">28643272</infon><infon key="section_type">REF</infon><infon key="source">Indian J Gastroenterol</infon><infon key="type">ref</infon><infon key="volume">36</infon><infon key="year">2017</infon><offset>30087</offset><text>Prevalence and risk factors for low bone mineral density in ulcerative colitis.</text></passage><passage><infon key="fpage">938</infon><infon key="lpage">45</infon><infon key="name_0">surname:Cushing;given-names:KC</infon><infon key="name_1">surname:Chen;given-names:YH</infon><infon key="name_2">surname:Du;given-names:XM</infon><infon key="pub-id_pmid">36680554</infon><infon key="section_type">REF</infon><infon key="source">Inflamm Bowel Dis</infon><infon key="type">ref</infon><infon key="volume">29</infon><infon key="year">2023</infon><offset>30167</offset><text>Risk variants in or near ZBTB40 AND NFATC1 increase the risk of both IBD and adverse bone health outcomes highlighting common genetic underpinnings across both diseases.</text></passage><passage><infon key="fpage">910</infon><infon key="lpage">4</infon><infon key="name_0">surname:Farraj;given-names:KL</infon><infon key="name_1">surname:Pellegrini;given-names:JR</infon><infon key="name_2">surname:Munshi;given-names:RF</infon><infon key="pub-id_pmid">36514507</infon><infon key="section_type">REF</infon><infon key="source">JGH Open</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">2022</infon><offset>30337</offset><text>Chronic steroid use: an overlooked impact on patients with inflammatory bowel disease.</text></passage><passage><infon key="fpage">3542</infon><infon key="lpage">7</infon><infon key="name_0">surname:Graziano;given-names:EJ</infon><infon key="name_1">surname:Vaughn;given-names:BP</infon><infon key="name_2">surname:Wang;given-names:Q</infon><infon key="name_3">surname:Chow;given-names:LS</infon><infon key="name_4">surname:Campbell;given-names:JP</infon><infon key="pub-id_pmid">33063187</infon><infon key="section_type">REF</infon><infon key="source">Dig Dis Sci</infon><infon key="type">ref</infon><infon key="volume">66</infon><infon key="year">2021</infon><offset>30424</offset><text>Microscopic colitis is not an independent risk factor for low bone density.</text></passage><passage><infon key="fpage">S276</infon><infon key="name_0">surname:Khan;given-names:N</infon><infon key="name_1">surname:Abbas;given-names:A</infon><infon key="name_2">surname:Khan;given-names:A</infon><infon key="section_type">REF</infon><infon key="source">J Crohns Colitis</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2013</infon><offset>30500</offset><text>Bone disease in male veterans with ulcerative colitis: 10-year nationwide study.</text></passage><passage><infon key="fpage">2368</infon><infon key="lpage">75</infon><infon key="name_0">surname:Khan;given-names:N</infon><infon key="name_1">surname:Abbas;given-names:AM</infon><infon key="name_2">surname:Almukhtar;given-names:RM</infon><infon key="name_3">surname:Khan;given-names:A</infon><infon key="pub-id_pmid">23596137</infon><infon key="section_type">REF</infon><infon key="source">J Clin Endocrinol Metab</infon><infon key="type">ref</infon><infon key="volume">98</infon><infon key="year">2013</infon><offset>30581</offset><text>Prevalence and predictors of low bone mineral density in males with ulcerative colitis.</text></passage><passage><infon key="fpage">346</infon><infon key="lpage">53</infon><infon key="name_0">surname:Khan;given-names:ZAW</infon><infon key="name_1">surname:Shetty;given-names:S</infon><infon key="name_2">surname:Pai;given-names:GC</infon><infon key="name_3">surname:Acharya;given-names:KKV</infon><infon key="name_4">surname:Nagaraja;given-names:R</infon><infon key="pub-id_pmid">32940845</infon><infon key="section_type">REF</infon><infon key="source">Indian J Gastroenterol</infon><infon key="type">ref</infon><infon key="volume">39</infon><infon key="year">2020</infon><offset>30669</offset><text>Prevalence of low bone mineral density in inflammatory bowel disease and factors associated with it.</text></passage><passage><infon key="fpage">904</infon><infon key="lpage">14</infon><infon key="name_0">surname:Lo;given-names:B</infon><infon key="name_1">surname:Holm;given-names:JP</infon><infon key="name_2">surname:Vester-Andersen;given-names:MK</infon><infon key="name_3">surname:Bendtsen;given-names:F</infon><infon key="name_4">surname:Vind;given-names:I</infon><infon key="name_5">surname:Burisch;given-names:J</infon><infon key="pub-id_pmid">32016388</infon><infon key="section_type">REF</infon><infon key="source">J Crohns Colitis</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">2020</infon><offset>30770</offset><text>Incidence, risk factors and evaluation of osteoporosis in patients with inflammatory bowel disease: a Danish population-based inception cohort with 10 years of follow-up.</text></passage><passage><infon key="fpage">175628481986215</infon><infon key="name_0">surname:Miranda-Bautista;given-names:J</infon><infon key="name_1">surname:Verdejo;given-names:C</infon><infon key="name_2">surname:Díaz-Redondo;given-names:A</infon><infon key="section_type">REF</infon><infon key="source">Therap Adv Gastroenterol</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2019</infon><offset>30941</offset><text>Metabolic bone disease in patients diagnosed with inflammatory bowel disease from Spain.</text></passage><passage><infon key="fpage">252</infon><infon key="lpage">60</infon><infon key="name_0">surname:Morrow;given-names:R</infon><infon key="name_1">surname:de Zoeten;given-names:EF</infon><infon key="name_2">surname:Ma;given-names:NN</infon><infon key="name_3">surname:Chun;given-names:C</infon><infon key="name_4">surname:Scott;given-names:FI</infon><infon key="pub-id_pmid">38374562</infon><infon key="section_type">REF</infon><infon key="source">J Pediatr Gastroenterol Nutr</infon><infon key="type">ref</infon><infon key="volume">78</infon><infon key="year">2024</infon><offset>31030</offset><text>Bone health screening practices with dual-energy X-ray absorptiometry and prediction of abnormal results in pediatric inflammatory bowel disease.</text></passage><passage><infon key="fpage">415</infon><infon key="lpage">22</infon><infon key="name_0">surname:Navaneethan;given-names:U</infon><infon key="name_1">surname:Shen;given-names:L</infon><infon key="name_2">surname:Venkatesh;given-names:PG</infon><infon key="pub-id_pmid">21939915</infon><infon key="section_type">REF</infon><infon key="source">J Crohns Colitis</infon><infon key="type">ref</infon><infon key="volume">5</infon><infon key="year">2011</infon><offset>31176</offset><text>Influence of ileal pouch anal anastomosis on bone loss in ulcerative colitis patients.</text></passage><passage><infon key="fpage">3528</infon><infon key="lpage">31</infon><infon key="name_0">surname:de Silva;given-names:AP</infon><infon key="name_1">surname:Karunanayake;given-names:AL</infon><infon key="name_2">surname:Dissanayaka;given-names:TG</infon><infon key="pub-id_pmid">19630109</infon><infon key="section_type">REF</infon><infon key="source">World J Gastroenterol</infon><infon key="type">ref</infon><infon key="volume">15</infon><infon key="year">2009</infon><offset>31263</offset><text>Osteoporosis in adult Sri Lankan inflammatory bowel disease patients.</text></passage><passage><infon key="fpage">593</infon><infon key="lpage">600</infon><infon key="name_0">surname:Semeao;given-names:EJ</infon><infon key="name_1">surname:Jawad;given-names:AF</infon><infon key="name_2">surname:Stouffer;given-names:NO</infon><infon key="name_3">surname:Zemel;given-names:BS</infon><infon key="name_4">surname:Piccoli;given-names:DA</infon><infon key="name_5">surname:Stallings;given-names:VA</infon><infon key="pub-id_pmid">10547248</infon><infon key="section_type">REF</infon><infon key="source">J Pediatr</infon><infon key="type">ref</infon><infon key="volume">135</infon><infon key="year">1999</infon><offset>31333</offset><text>Risk factors for low bone mineral density in children and young adults with Crohn’s disease.</text></passage><passage><infon key="fpage">669</infon><infon key="lpage">76</infon><infon key="name_0">surname:Schüle;given-names:S</infon><infon key="name_1">surname:Rossel;given-names:JB</infon><infon key="name_2">surname:Frey;given-names:D</infon><infon key="section_type">REF</infon><infon key="source">United European Gastroenterol J</infon><infon key="type">ref</infon><infon key="volume">4</infon><infon key="year">2016</infon><offset>31428</offset><text>Prediction of low bone mineral density in patients with inflammatory bowel diseases.</text></passage><passage><infon key="fpage">79</infon><infon key="lpage">84</infon><infon key="name_0">surname:Tsironi;given-names:E</infon><infon key="name_1">surname:Hadjidakis;given-names:D</infon><infon key="name_2">surname:Mallas;given-names:E</infon><infon key="name_3">surname:Tzathas;given-names:C</infon><infon key="name_4">surname:Karamanolis;given-names:DG</infon><infon key="name_5">surname:Ladas;given-names:SD</infon><infon key="pub-id_pmid">18398269</infon><infon key="section_type">REF</infon><infon key="source">J Musculoskelet Neuronal Interact</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="year">2008</infon><offset>31513</offset><text>Comparison of T- and Z-score in identifying risk factors of osteoporosis in inflammatory bowel disease patients.</text></passage><passage><infon key="fpage">278</infon><infon key="lpage">85</infon><infon key="name_0">surname:Targownik;given-names:LE</infon><infon key="name_1">surname:Bernstein;given-names:CN</infon><infon key="name_2">surname:Nugent;given-names:Z</infon><infon key="name_3">surname:Leslie;given-names:WD</infon><infon key="pub-id_pmid">23103821</infon><infon key="section_type">REF</infon><infon key="source">Clin Gastroenterol Hepatol</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">2013</infon><offset>31626</offset><text>Inflammatory bowel disease has a small effect on bone mineral density and risk for osteoporosis.</text></passage><passage><infon key="fpage">1</infon><infon key="lpage">10</infon><infon key="name_0">surname:Yin;given-names:Y</infon><infon key="name_1">surname:Lu;given-names:X</infon><infon key="name_2">surname:Li;given-names:Z</infon><infon key="section_type">REF</infon><infon key="source">Gastroenterol Res Pract</infon><infon key="type">ref</infon><infon key="volume">2022</infon><infon key="year">2022</infon><offset>31723</offset><text>Risk factors for worsening of bone loss in patients newly diagnosed with inflammatory bowel disease.</text></passage><passage><infon key="fpage">384</infon><infon key="lpage">413</infon><infon key="name_0">surname:Rubin;given-names:DT</infon><infon key="name_1">surname:Ananthakrishnan;given-names:AN</infon><infon key="name_2">surname:Siegel;given-names:CA</infon><infon key="name_3">surname:Sauer;given-names:BG</infon><infon key="name_4">surname:Long;given-names:MD</infon><infon key="pub-id_pmid">30840605</infon><infon key="section_type">REF</infon><infon key="source">Am J Gastroenterol</infon><infon key="type">ref</infon><infon key="volume">114</infon><infon key="year">2019</infon><offset>31824</offset><text>ACG clinical guideline: ulcerative colitis in adults.</text></passage><passage><infon key="fpage">481</infon><infon key="lpage">517</infon><infon key="name_0">surname:Lichtenstein;given-names:GR</infon><infon key="name_1">surname:Loftus;given-names:EV</infon><infon key="name_2">surname:Isaacs;given-names:KL</infon><infon key="name_3">surname:Regueiro;given-names:MD</infon><infon key="name_4">surname:Gerson;given-names:LB</infon><infon key="name_5">surname:Sands;given-names:BE</infon><infon key="pub-id_pmid">29610508</infon><infon key="section_type">REF</infon><infon key="source">Am J Gastroenterol</infon><infon key="type">ref</infon><infon key="volume">113</infon><infon key="year">2018</infon><offset>31878</offset><text>ACG clinical guideline: management of crohn’s disease in adults.</text></passage><passage><infon key="fpage">1606</infon><infon key="lpage">19</infon><infon key="name_0">surname:Ordás;given-names:I</infon><infon key="name_1">surname:Eckmann;given-names:L</infon><infon key="name_2">surname:Talamini;given-names:M</infon><infon key="name_3">surname:Baumgart;given-names:DC</infon><infon key="name_4">surname:Sandborn;given-names:WJ</infon><infon key="pub-id_pmid">22914296</infon><infon key="section_type">REF</infon><infon key="source">Lancet</infon><infon key="type">ref</infon><infon key="volume">380</infon><infon key="year">2012</infon><offset>31945</offset><text>Ulcerative colitis.</text></passage><passage><infon key="fpage">908727</infon><infon key="name_0">surname:Laurent;given-names:MR</infon><infon key="name_1">surname:Goemaere;given-names:S</infon><infon key="name_2">surname:Verroken;given-names:C</infon><infon key="pub-id_pmid">35757436</infon><infon key="section_type">REF</infon><infon key="source">Front Endocrinol (Lausanne)</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2022</infon><offset>31965</offset><text>Prevention and treatment of glucocorticoid-induced osteoporosis in adults: consensus recommendations from the belgian bone club.</text></passage><passage><infon key="fpage">2496</infon><infon key="lpage">508</infon><infon key="name_0">surname:Feuerstein;given-names:JD</infon><infon key="name_1">surname:Ho;given-names:EY</infon><infon key="name_2">surname:Shmidt;given-names:E</infon><infon key="pub-id_pmid">34051983</infon><infon key="section_type">REF</infon><infon key="source">Gastroenterology</infon><infon key="type">ref</infon><infon key="volume">160</infon><infon key="year">2021</infon><offset>32094</offset><text>American Gastroenterological Association clinical practice guideline on the medical management of moderate to severe luminal and fistulizing crohn’s disease.</text></passage><passage><infon key="fpage">417</infon><infon key="lpage">29</infon><infon key="name_0">surname:Podolsky;given-names:DK</infon><infon key="pub-id_pmid">12167685</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">347</infon><infon key="year">2002</infon><offset>32254</offset><text>Inflammatory bowel disease.</text></passage><passage><infon key="fpage">228</infon><infon key="lpage">33</infon><infon key="name_0">surname:Bjarnason;given-names:I</infon><infon key="name_1">surname:Macpherson;given-names:A</infon><infon key="name_2">surname:Mackintosh;given-names:C</infon><infon key="name_3">surname:Buxton-Thomas;given-names:M</infon><infon key="name_4">surname:Forgacs;given-names:I</infon><infon key="name_5">surname:Moniz;given-names:C</infon><infon key="pub-id_pmid">9071937</infon><infon key="section_type">REF</infon><infon key="source">Gut</infon><infon key="type">ref</infon><infon key="volume">40</infon><infon key="year">1997</infon><offset>32282</offset><text>Reduced bone density in patients with inflammatory bowel disease.</text></passage><passage><infon key="fpage">42</infon><infon key="lpage">51</infon><infon key="name_0">surname:Walther;given-names:F</infon><infon key="name_1">surname:Fusch;given-names:C</infon><infon key="name_2">surname:Radke;given-names:M</infon><infon key="name_3">surname:Beckert;given-names:S</infon><infon key="name_4">surname:Findeisen;given-names:A</infon><infon key="pub-id_pmid">16819376</infon><infon key="section_type">REF</infon><infon key="source">J Pediatr Gastroenterol Nutr</infon><infon key="type">ref</infon><infon key="volume">43</infon><infon key="year">2006</infon><offset>32348</offset><text>Osteoporosis in pediatric patients suffering from chronic inflammatory bowel disease with and without steroid treatment.</text></passage><passage><infon key="fpage">7588</infon><infon key="lpage">606</infon><infon key="name_0">surname:Guo;given-names:Y</infon><infon key="name_1">surname:Zhang;given-names:T</infon><infon key="name_2">surname:Wang;given-names:Y</infon><infon key="name_3">surname:Liu;given-names:R</infon><infon key="name_4">surname:Chang;given-names:M</infon><infon key="name_5">surname:Wang;given-names:X</infon><infon key="pub-id_pmid">34231596</infon><infon key="section_type">REF</infon><infon key="source">Food Funct</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2021</infon><offset>32469</offset><text>Effects of oral vitamin D supplementation on inflammatory bowel disease: a systematic review and meta-analysis.</text></passage><passage><infon key="fpage">579</infon><infon key="lpage">90</infon><infon key="name_0">surname:Massironi;given-names:S</infon><infon key="name_1">surname:Viganò;given-names:C</infon><infon key="name_2">surname:Palermo;given-names:A</infon><infon key="pub-id_pmid">36933563</infon><infon key="section_type">REF</infon><infon key="source">Lancet Gastroenterol Hepatol</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="year">2023</infon><offset>32581</offset><text>Inflammation and malnutrition in inflammatory bowel disease.</text></passage><passage><infon key="fpage">S56</infon><infon key="name_0">surname:Dumitrescu;given-names:G</infon><infon key="name_1">surname:Nedelciuc;given-names:O</infon><infon key="name_2">surname:Badea;given-names:M</infon><infon key="name_3">surname:Dranga;given-names:M</infon><infon key="name_4">surname:Mihai;given-names:C</infon><infon key="name_5">surname:Cijevschi Prelipcean;given-names:C</infon><infon key="section_type">REF</infon><infon key="source">J Crohns Colitis</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2013</infon><offset>32642</offset><text>Vitamin D status and bone mineral density in patients recently diagnosed with Crohn’s disease.</text></passage><passage><infon key="fpage">S56</infon><infon key="name_0">surname:Dumitrescu;given-names:G</infon><infon key="name_1">surname:Pintilie;given-names:IA</infon><infon key="name_2">surname:Dranga;given-names:M</infon><infon key="name_3">surname:Toader;given-names:E</infon><infon key="name_4">surname:Mihai;given-names:C</infon><infon key="name_5">surname:Cijevschi Prelipcean;given-names:C</infon><infon key="section_type">REF</infon><infon key="source">J Crohns Colitis</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2013</infon><offset>32739</offset><text>Vitamin D status and bone mineral density in patients recently diagnosed with ulcerative colitis.</text></passage><passage><infon key="fpage">5362</infon><infon key="lpage">74</infon><infon key="name_0">surname:Kärnsund;given-names:S</infon><infon key="name_1">surname:Lo;given-names:B</infon><infon key="name_2">surname:Bendtsen;given-names:F</infon><infon key="name_3">surname:Holm;given-names:J</infon><infon key="name_4">surname:Burisch;given-names:J</infon><infon key="pub-id_pmid">32994694</infon><infon key="section_type">REF</infon><infon key="source">World J Gastroenterol</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">2020</infon><offset>32837</offset><text>Systematic review of the prevalence and development of osteoporosis or low bone mineral density and its risk factors in patients with inflammatory bowel disease.</text></passage><passage><infon key="fpage">18</infon><infon key="name_0">surname:Zhou;given-names:TY</infon><infon key="name_1">surname:Pan;given-names:JQ</infon><infon key="name_2">surname:Lai;given-names:B</infon><infon key="pub-id_pmid">32072320</infon><infon key="section_type">REF</infon><infon key="source">Clin Transl Med</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2020</infon><offset>32999</offset><text>Bone mineral density is negatively correlated with ulcerative colitis: a systematic review and meta-analysis.</text></passage></document>
</collection>